Serum free light chains and the risk of ESRD and death in CKD

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 12, 2011, Pages 2829-2837

  Haynes, Richard ^a,b   Hutchison, Colin A ^c   Emberson, Jonathan ^a   Dasgupta, Tanaji ^a,b   Wheeler, David C ^d   Townend, John N ^c   Landray, Martin J ^a   Cockwell, Paul ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HEART INJURY; HUMAN; IMMUNOELECTROPHORESIS; IMMUNOGLOBULIN BLOOD LEVEL; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MORTALITY; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; CHRONIC DISEASE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARAPROTEINEMIAS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 83155175920     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03350411     Document Type: Article

References (39)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047, 2007
2. Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, Dekker FW: Screening strategies for chronic kidney disease in the general population: Follow-up of cross sectional health survey. BMJ 333: 1047, 2006
3. Stevens PE, O'Donoghue DJ, de Lusignan S, Van Vlymen J, Klebe B, Middleton R, Hague N, New J, Farmer CK: Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int 72: 92-99, 2007
4. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX: Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 17: 2034-2047, 2006
5. O'Hare AM, Choi AI, Bertenthal D, Bacchetti P, Garg AX, Kaufman JS, Walter LC, Mehta KM, Steinman MA, Allon M, McClellan WM, Landefeld CS: Age affects outcomes in chronic kidney disease. J Am Soc Nephrol 18: 2758-2765, 2007
6. Baigent C, Burbury K, Wheeler D: Premature cardiovascular disease in chronic renal failure. Lancet 356: 147-152, 2000
7. Solomon A: Light chains of human immunoglobulins. Methods Enzymol 116: 101-121, 1985
8. Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA: Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 51: 878-881, 2005
9. Hutchison CA, Basnayake K, Cockwell P: Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nat Rev Nephrol 5: 621-628, 2009
10. Basnayake K, Stringer SJ, Hutchison CA, Cockwell P: The biology of immunoglobulin free light chains and kidney injury. Kidney Int 79: 1289-1301, 2011
11. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, Cockwell P: Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 3: 1684-1690, 2008
12. Solling K, Solling J, Romer FK: Free light chains of immunoglobulins in serum from patients with rheumatoid arthritis, sarcoidosis, chronic infections and pulmonary cancer. Acta Med Scand 209: 473-477, 1981
13. Gottenberg JE, Aucouturier F, Goetz J, Sordet C, Jahn I, Busson M, Cayuela JM, Sibilia J, Mariette X: Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis 66: 23-27, 2007
14. Cohen G: Immunoglobulin light chains in uremia. Kidney Int Suppl May: S15-S18, 2003
15. Landray MJ, Thambyrajah J, McGlynn FJ, Jones HJ, Baigent C, Kendall MJ, Townend JN, Wheeler DC: Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. Am J Kidney Dis 38: 537-546, 2001
16. Landray MJ, Wheeler DC, Lip GY, Newman DJ, Blann AD, McGlynn FJ, Ball S, Townend JN, Baigent C: Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: The Chronic Renal Impairment in Birmingham (CRIB) study. Am J Kidney Dis 43: 244-253, 2004
17. Zehnder D, Landray MJ, Wheeler DC, Fraser W, Blackwell L, Nuttall S, Hughes SV, Townend J, Ferro C, Baigent C, Hewison M: Cross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of predialysis patients. The Chronic Renal Impairment in Birmingham (CRIB) study. Nephron Clin Pract 107: c109-c116, 2007
18. Landray MJ, Emberson JR, Blackwell L, Dasgupta T, Zakeri R, Morgan MD, Ferro CJ, Vickery S, Ayrton P, Nair D, Dalton RN, Lamb EJ, Baigent C, Townend JN, Wheeler DC: Prediction of ESRD and death among people with CKD: The Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am J Kidney Dis 56: 1082-1094, 2010
19. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, Drew R: Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47: 673-680, 2001
20. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, Kyle RA: Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clin Chem 48: 1437-1444, 2002
21. Hutchison CA, Plant T, Drayson M, Cockwell P, Kountouri M, Basnayake K, Harding S, Bradwell AR, Mead G: Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol 9: 11, 2008
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470, 1999
23. Plummer M: Improved estimates of floating absolute risk. Stat Med 23: 93-104, 2004
24. Beetham R, Wassell J, Wallage MJ, Whiteway AJ, James JA: Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies? Ann Clin Biochem 44: 516-522, 2007
25. Vermeersch P, Van Hoovels L, Delforge M, Marien G, Bossuyt X: Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder. Br J Haematol 143: 496-502, 2008
26. Hill PG, Forsyth JM, Rai B, Mayne S: Serum free light chains: An alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. Clin Chem 52: 1743-1748, 2006
27. Rajkumar SV, Kyle RA, Therneau TM, Melton LJ, 3rd, Bradwell AR, Clark RJ, Larson DR, Plevak MF, Dispenzieri A, Katzmann JA: Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106: 812-817, 2005
28. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton III LJ, Colby CL, Therneau TM, Clark R, Kumar SK, Bradwell A, Fonseca R, Jelinek DF, Rajkumar SV: Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: A retrospective population-based cohort study. Lancet 375: 1721-1728, 2010
29. Blade J: Clinical practice. Monoclonal gammopathy of undetermined significance. N Engl J Med 355: 2765-2770, 2006
30. Li M, Hering-Smith KS, Simon EE, Batuman V: Myeloma light chains induce epithelial-mesenchymal transition in human renal proximal tubule epithelial cells. Nephrol Dial Transplant 23: 860-870, 2008
31. Pote A, Zwizinski C, Simon EE, Meleg-Smith S, Batuman V: Cytotoxicity of myeloma light chains in cultured human kidney proximal tubule cells. Am J Kidney Dis 36: 735-744, 2000
32. Sengul S, Zwizinski C, Batuman V: Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. Am J Physiol Renal Physiol 284: F1245-F1254, 2003
33. Sengul S, Zwizinski C, Simon EE, Kapasi A, Singhal PC, Batuman V: Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells. Kidney Int 62: 1977-1988, 2002
34. Wang PX, Sanders PW: Immunoglobulin light chains generate hydrogen peroxide. J Am Soc Nephrol 18: 1239-1245, 2007
35. Ying WZ, Wang PX, Aaron KJ, Basnayake K, Sanders PW: Immunoglobulin light chains activate nuclear factor-kappaB in renal epithelial cells through a Src-dependent mechanism. Blood 117: 1301-1307, 2011
36. Batuman V: Proximal tubular injury in myeloma. Contrib Nephrol 153: 87-104, 2007
37. Fisher MA, Borgnakke WS, Taylor GW: Periodontal disease as a risk marker in coronary heart disease and chronic kidney disease. Curr Opin Nephrol Hypertens 19: 519-526, 2010
38. Cohen G, Haag-Weber M, Mai B, Deicher R, Horl WH: Effect of immunoglobulin light chains from hemodialysis and continuous ambulatory peritoneal dialysis patients on polymorphonuclear leukocyte functions. J Am Soc Nephrol 6: 1592-1599, 1995
39. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R: Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 150: 341-353, 1999